Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a clinical-stage biotechnology company focusing on development, production, and commercialization of innovative metabolic immunotherapies, has signed a comprehensive strategic cooperation agreement with Xiangxue Life Science Technology (Guangdong) Co., Ltd. (hereinafter referred to as "Xiangxue Life Sciences"). The two parties will apply their respective technological advantages to fully explore the combined application of Meta 10 metabolic reprogramming technology and TCR-T cell therapy products in the treatment of solid tumors.

Recently, a breakthrough result was achieved in an IIT clinical study of Leman Biotech’s metabolically enhanced CD19 CAR-T injection, with the first patient achieving complete remission after treatment at a very low dose. The results received widespread attention from medias and investors, and the co-founder of Leman Biotech was interviewed by media “Intellectual Medicine Bureau” to share the specifics of the clinical study and how AI can be incorporated into next-generation solid tumor CAR-T design as the follows.

On May 25, at the China AI Drug Discovery Conference held in Shanghai, Dr. Jian Ma, co-founder and CEO of XtalPi, hosted the brand launch event of XtalPi Pharma under the theme of "Smart New Life, Leading the Future." XtalPi Pharma is an exclusive brand focusing on early-stage R&D of innovative drugs, powered by advanced AI technology. It boasts two distinct technology platforms: ID4Inno™ for innovative small molecule discovery and XupremAb™ for next-generation innovative large molecule discovery.

Leman Biotech Co., Ltd. (referred to as "Leman Biotech" or "the company") is pleased to announce the successful treatment of the first patient using its metabolically enhanced CD19 CAR-T therapy (Meta10-19). The patient, enrolled in an investigator-initiated trial (IIT) at the First Affiliated Hospital of the University of Science and Technology of China, has achieved complete remission and was subsequently discharged from the hospital. This clinical trial (NCT05715606) was officially initiated in early 2023 to evaluate the safety and efficacy of Leman Biotech's Metabolically Enhanced CAR-T System. The CD19, a well-studied antigen, was chosen as the therapeutic target to gather preliminary clinical data and accelerate the development of future metabolically enhanced CAR-T cell therapies for solid tumors.

On May 10, 36 Kr, a well-known Chinese venture capital platform, released the 2023 "36 Under 36" list of entrepreneurs and investors, which has garnered extensive trust and attention within the venture capital community.

Dr. Dudu Tong, the R&D Director of Leman Biotech, has been actively participating in discussions and conferences related to the application of artificial intelligence (AI) in the biotech industry. As AI continues to generate significant interest and expectations, Leman Biotech's AI pipeline has achieved remarkable milestones, gaining attention in the field.

Leman Biotech, in collaboration with XtalPi Technology, has reached a significant milestone in the AI Enabled Superkine pipeline. Using the MetaAI-10 computational model and yeast demonstration technology, Leman Biotech successfully conducted high-throughput screening of superkine mutants, resulting in over 5000 immunometabolic regulators with exceptionally high affinity. Patent application (number: 2022116277856) has been filed for the invention.

Leman Biotech received the prestigious "CGT Industry Star" Technology Breakthrough of the Year award at the CGT Asia 2023 3rd Asia Cell and Gene Therapy Innovation Summit held in Shanghai on April 3-4, 2023. Dr. Dudu Tong, R&D Director of Leman Biotech, received the award on behalf of the company.